| HOME >> BIOLOGY >> TECHNOLOGY |
RIDGEFIELD, Conn., Oct. 12 /PRNewswire/ -- Boehringer Ingelheim today announced that the company has been awarded top honors by Science as the world's most respected biopharmaceutical employer. Science's annual survey of more than 470 Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries. Respondents to the web-based survey are asked to rate companies based on 23 driving characteristics, including corporate image, leadership and direction, financial strength, company culture, work/life balance, compensation, and benefits, as well as being easily adaptable to change and having a thriving research-driven environment.
"We are very pleased to be recognized as a global leader in the pharmaceutical industry by Science," said J. Martin Carroll, president and chief executive officer of Boehringer Ingelheim Corporation. "It is especially gratifying to receive this honor knowing it is a measurement of corporate reputation among both our employees and the employees of our competitors. This international recognition truly signifies that Boehringer Ingelheim is an Employer of Choice in the United States and around the world."
Over the past few years that Science has carried out this survey, Boehringer Ingelheim has climbed up in ranking, from 8th place in 2005 to second place last year. This year, Boehringer Ingelheim reached the top ranking, recognizing the company's strong commitment to innovative thinking throughout the product pipeline, from the laboratory to the marketplace, while establishing an excellent working environment.
Like Science's 2006 ranking of biopharma employers, the 2007 survey
sought to identify the companies with the best reputations as employers,
based on 3,157 survey responses from readers of Science and other
respondents in industry. Twenty-nine percent of respondents came from
outside of the United States, primarily Western Europe, and more than 90
percent worked in privat
'/>"/>
| SOURCE Boehringer Ingelheim Copyright©2007 PR Newswire. All rights reserved |